R. D’Anna

发表

Hereditary cancer risk assessment and genetic testing in the community urology practice setting

H. Korman, T. Slavin, D. Iliev, 2022, The Prostate.

One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume® Drug-Coated Balloon for Anterior Urethral Strictures

C. Olsson, S. Elliott, S. Brandes, 2021, The Journal of urology.

JU Insight One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume Drug-Coated Balloon for Anterior Urethral Strictures

S. Elliott, S. Brandes, B. Erickson, 2021 .

LBA02-03 CAN TURBT BE AVOIDED? PRIMARY CHEMOABLATION WITH A REVERSE THERMAL GEL CONTAINING MITOMYCIN (UGN-102) IN PATIENTS WITH LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER

J. Raman, K. Chamie, D. Morris, 2020 .

Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score

T. Morgan, S. Stone, S. Kaul, 2019, Personalized medicine.

MP56-07 INTERIM RESULTS FOR THE ROBUST III TRIAL EVALUATING THE OPTILUME DRUG COATED BALLOON FOR ANTERIOR URETHRAL STRICTURES

S. Elliott, R. Virasoro, K. Coutinho, 2021 .

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

J. Raman, William C. Huang, K. Chamie, 2021, The Journal of urology.

The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

A. Te, M. Jalkut, J. Kaminetsky, 2023, The Journal of urology.